Afiliación
Vice Presidente Ejecutivo Asociado de la Universidad de Tohoku
Asesor ejecutivo del decano de la Universidad de Tohoku Cargos actuales
Miembro de la Real academia de medicina en Bélgica (2004-presente)
Miembro del Comité ejecutivo de la Sociedad internacional de nefrología (2013)
Presidente de “Fortaleciendo la sociedad entre JSN y ISN, Sociedad japonesa de nefrología (2008’2010)
Profesor adjunto de la Facultad de Medicina Feinberg, Universidad de North Western(2012- presente)
Biografía
El profesor Miyata nació en Japón en el año 1961. Obtuvo los títulos de M.D y Ph.D en la Universidad de Nagoya en los años 1986 y 1991, respectivamente. Es miembro permanente de la Real Academia
de Medicina en Bélgica, miembro del comité ejecutivo y asesor en la Sociedad Internacional de Nefrología (ISN), presidente del comité “Fortaleciendo la sociedad entre JSN y ISN de la
sociedad japonesa de nefrologia (JSN).
Entre las 250 publicaciones en inglés se pueden destacar la identificación de genes en desórdenes moleculares de varias enfermedades hereditarias, la delineación de mecanismos implicados en la
nefropatía diabética y su prevención. También se destaca la fisiopatología de la toxicidad urémica (carbonyl stress) y su tratamiento, así como el rol de moléculas bioactivas y su inhibición
(PAI-1, oxygen sensor , megsin, etc). Su laboratorio actualmente desarrolla una nueva área de investigación que combina la ciencia médica, biología estructural, química, farmacología e ingeniería
en computación con el objetivo de trasladar varias moléculas que han sido identificadas, desde la investigación básica a la clínica.
Los proyectos están actualmente en la fase preclínica (PAI-1 inhibitor, Oxygen sensor inhibitor) o clínica IIa (carbonyl stress inhibitor)
Premiaciones
Sociedad japonesa de medicina molecular (2002)
Fundación japonesa para la salud y envejecimiento (2001)
Premio Oshima de la Sociedad japonesa de nefrologia (1995)
Premio al investigador joven de la Sociedad japonesa de medicina interna (1993)
Premio Nagoya memorial (1991)
Publicaciones
Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress.Itokawa M, Miyashita M, Arai M, Dan T, Takahashi K, Tokunaga T, Ishimoto K, Toriumi K, Ichikawa T, Horiuchi Y, Kobori A, Usami S, Yoshikawa T, Amano N, Washizuka S, Okazaki Y, Miyata T.
Psychiatry Clin Neurosci. 2018;72(1):35-44.
A null mutation in SERPINE1 protects against biological aging in humans.Khan SS, Shah SJ,Klyachko E, Baldridge AS, Eren M, Place AT, Aviv A, Puterman E, Lloyd-Jones DM, Heiman M, Miyata T, Gupta S, Shapiro AD, Vaughan DE.
Science Advances.2017;3:eaao1617.
TGF-β-induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche.
Yahata T, Ibrahim A, Muguruma Y, Eren M, Shaffer AM, Watanabe N, Kaneko S, Nakabayashi N, Dan T, Hirayama N, Vaughan DE, Miyata T, Ando K.
Blood.2017;130(21):2283-2294.
PAI-1 is a critical regulator of FGF23 homeostasis.
Eren M, Place AT, Thomas PM, Flevaris P, Miyata T, Vaughan DE.
Science Advances.2017;3: e1603259
Plasminogen activator inhibitor-1 regulates macrophage-dependent postoperative adhesion by enhancing EGF-HER1 signaling in mice.
Honjo T, Munakata S, Tashiro Y, Salama Y, Shimazu H, Eiamboonsert S, Dhahri D, Ichimura A, Dan T, Miyata T, Takeda K, Sakamoto K, Hattori K, Heissig B.
The FASEB Journal.2017 ;31:2625-2637
A small molecule inhibitor of PAI-1 protects against Doxorubicin-induced cellular senescence: molecular basis.
Ghosh AK, Rai R, Park KE, Eren M, Miyata T, Wilsbacher LD, Vaughan DE.
Oncotarget.2016; 7:72443-72457
Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma.
Liu RM, Eldridge S, Watanabe N, Deshane J, Kuo HC, Jiang C, Wang Y, Liu G, Schwiebert L, Miyata T, Thannickal VJ.
Am J Physiol Lung Cell Mol Physiol.2016; 15: 328-336.
Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model.
Jeong BY, Uddin MJ, Park JH, Lee JH, Lee HB, Miyata T, Ha H.
PLoS One.2016; 11: e0157012.
A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice.
Piao L,Jung I, Huh JY, Miyata T, Ha H.
British J Pharmacology.2016; 173:2622-2632.
Delayed intervention with pyridoxamine improves metabolic function and prevents adipose tissue inflammation and insulin resistance in high-fat diet-induced obese mice.
Maessen DE, Brouwers O, Gaens KH, Wouters K, Cleutjens JP, Janssen BJ, Miyata T, Stehouwer CD, Schalkwijk CG.
Diabetes.2016; 65: 956-966.
Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.
Placencio VR, Ichimura A, Miyata T, DeClerck YA.
PLoS One.2015; 10: e0133786.
Erythropoietin Synthesis in Renal Myofibroblasts Is Restored by Activation of Hypoxia Signaling.
Souma T, Nezu M, Nakano D, Yamazaki S, Hirano I, Sekine H, Dan T, Takeda K, Fong GH, Nishiyama A, Ito S, Miyata T, Yamamoto M, Suzuki N.
J Am Soc Nephrol.2016; 27: 428-438.
Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis.
Pelisch N, Dan T, Ichimura A, Sekiguchi H, Vaughan DE, van Ypersele de Strihou C, Miyata T.
PLoS One. 2015; 10: e0124510.
Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via beta 1 integrin endocytosis.
Kobayashi N, Ueno T, Ohashi K, Yamashita H, Takahashi Y, Sakamoto K, Manabe S, Hara S, Takashima Y, Dan T, Pastan I, Miyata T, Kurihara H, Matsusaka T, Reiser J, Nagata M.
Am J Physiol Renal Physiol.2015; 308:F614-26.
Nitric oxide prevents alveolar senescence and emphysema in a mouse model.
Boe AE, Eren M, Morales-Nebreda L, Murphy SB, Budinger GR, Mutlu GM, Miyata T, Vaughan DE.
PLoS One. 2015; 10: e0116504
PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice
Eren M, Boe A, Murphy SB, Place AT, Nagpal V, Morales-Nebreda L, Urich D, Quaggin SE, Budinger GS, Mutlu GM, Miyata T, Vaughan DE.
Proc Natl Acad Sci USA. 2014; 111: 7090-7095.
Drug discovery in renal disease —towards a more efficient framework
Miyata T, Ando T, Hiragi H, Watanabe K, Yamamoto F, Vaughan DE, Kurokawa T, Oshima Y, van Ypersele de Strihou C, Takeuchi M.
Nat Rev Nephrol. 2014; 10: 290-296.
Inhibition of Plasminogen Activator Inhibitor Type-1 Activity Enhances Rapid and Sustainable Hematopoietic Regeneration
Ibrahim A.A, Yahata T, Onizuka M, Dan T, van Ypersele de Strihou C, Miyata T, Ando K.
Stem Cells 2014; 32: 946-958.
Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes
Brouwers O, Niessen PM, Miyata T, Østergaard JA, Flyvbjerg A, Peutz-Kootstra CJ, Sieber J, Mundel PH, Brownlee M, Janssen BJ, De Mey JG, Stehouwer CD, Schalkwijk CG.
Diabetologia 2014; 57: 224-235.
The PAI-1 antagonist TM5441 attenuates L-NAME-induced hypertension and vascular senescence
Boe A, Eren M, Murphy S, Kamide1 C, Ichimura A, Terry D, McAnally D, Smith LH, Miyata T, Vaughan DE.
Circulation 2013; 128: 2318-2324.
Kidney failure: aims for the next 10 years and barriers to success
Remuzzi G, Benigni A, Finkelstein FO, Grunfeld JP, Joly D, Katz I, Liu ZH, Miyata T, Perico N, Rodriguez-Iturbe B, Antiga L, Schaefer F, Schieppati A, Schrier RW, Tonelli M.
Lancet 2013; 382: 353-362.
Diabetic nephropathy: Are there new and potentially promising therapies targeting oxygen biology?
Miyata T, Suzuki N, van Ypersele de Strihou C.
Kidney Int 2013; 84: 693-702.
A Small Molecule Inhibitor to Plasminogen Activator Inhibitor 1 Inhibits Macrophage Migration
Ichimura A, Matsumoto S, Suzuki S, Dan T, Yamaki S, Sato Y, Kiyomoto H, Ishii N, Okada K, Matsuo O, Hou FF, Vaughan DE, van Ypersele de Strihou C, Miyata T.
Arterioscler Thromb Vasc Biol. 2013; 33: 935-942.
Metabolic stress response implicated in diabetic retinopathy:the role of calpain, and the therapeutic impact of calpain inhibitor.
Shanab AY, Nakazawa T, Ryu M, Tanaka Y, Himori N, Taguchi K, Yasuda M, Watanabe R, Takano J, Takaomi S, Minegishi N, Miyata T, Abe T, Yamamoto M.
Neurobiology of Disease 2012; 48: 556-567.
The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis.
Zhou LL, Cao W, Xie C, Tian J, Zhou Z, Zhou Q, Zhu P, Li A, Liu Y, Miyata T, Hou FF, Nie J.
Kidney Int 2012; 82: 759-770.
Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice.
Tashiro Y, Nishida C, Sato-Kusubata K, Ohki-Koizumi M, Ishihara M, Sato A, Gritli I, Komiyama H, Sato Y, Dan T, Miyata T, Okumura K, Tomiki Y, Sakamoto K, Nakauchi H, Heissig B, Hattori K.
Blood 2012; 119: 6382-6393.
Protection against methylglyoxal-derived AGEs by regulation of glyoxalse-1 prevents retinal neuroglial and vasodegenerative pathology.
Berner AK, Brouwers O, Pringle R, Klaassen I, Colhoun L, McVicar C, Brockbank S, Curry JW, Miyata T, Brownlee M, Schlingemann RO, Schalkwijk C, Stitt AW. Diabetologia 2012; 55: 845-854.
Skin advanced glycation end product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men.
Momma H, Niu K, Kobayashi Y, Guan L, Sato M, Guo H, Chujo M, Otomo A, Yufei C, Tadaura H, Saito T, Mori T, Miyata T, Nagatomi R.
Osteoporos Int 2012; 23: 1673-1681.
Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis.
Huang WT, Vayalil PK, Miyata T, Hagood J, Liu RM.
Am J Respir Cell Mol Biol. 2012; 46: 87-95.
Glyoxalase I retards renal senescence.
Ikeda Y, Inagi R, Miyata T, Nagai R, Arai M, Miyashita M, Itokawa M, Fujita T, Nangaku M.
Am J Pathol 2011; 179: 2810-2821.
New era for drug discovery and development in renal disease.
Miyata T, Kikuchi K, Kiyomoyo H,van Ypersele de Strihou C.
Nat Rev Nephrol 2011;7:469-477.
In Oxidative Stress in Applied Basic Research and Clinical Practice: Studies on Renal Disorders (Springer),
edited by Toshio MIyata, Kai-Uwe Eckardt, Masaomi Nangaku.
Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: novel therapeutic targets.
Miyata T, Takizawa S,van Ypersele de Strihou C.
Am J Physiol Cell Physiol 2011;300:226-231.
Effect of Sevelamer and Calcium-Based Phosphate Binders on Coronary Artery Calcification and Accumulation of Circulating Advanced Glycation End Products in Hemodialysis Patients.
Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A.
Am J Kidney Dis 2011;57:422-431.
Overexpression of Glyoxalase-I Reduces Hyperglycemia–induced Levels of Advanced Glycation Endproducts and Oxidative Stress in Diabetic Rats.
Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, Teerlink T, Schrauwen P, Brownlee M, Stehouwer CD, Schalkwijk CG.
J Biol Chem. 2011 ;286:1374-1380.
Enhanced carbonyl stress in a subpopulation of schizophrenia.
Arai M, Yuzawa H, Nohara I, Ohnishi T, Obata N, Iwayama Y, Haga S, Toyota T, Ujike H, Arai M, Ichikawa T, Nishida A,Tanaka Y, Furukawa A, Aikawa Y, Kuroda O, Niizato K, Izawa R, Nakamura K, Mori N, Matsuzawa D, Hashimoto K, Iyo M, Sora I, Matsushita M, Okazaki Y, Yoshikawa T, Miyata T, Itokawa M.
Arch Gen Psychiatry 2010; 67: 589-597.
Diabetic nephropathy: a disorder of oxygen metabolism?
Miyata T, van Ypersele de Strihou C.
Nat Rev Nephrol. 2010;6:83-95.
Por favor haga referencia a lo siguiente para los detalles.